[go: up one dir, main page]

MX2008001838A - Sales y polimorfos de un inhibidor de vegf-r. - Google Patents

Sales y polimorfos de un inhibidor de vegf-r.

Info

Publication number
MX2008001838A
MX2008001838A MX2008001838A MX2008001838A MX2008001838A MX 2008001838 A MX2008001838 A MX 2008001838A MX 2008001838 A MX2008001838 A MX 2008001838A MX 2008001838 A MX2008001838 A MX 2008001838A MX 2008001838 A MX2008001838 A MX 2008001838A
Authority
MX
Mexico
Prior art keywords
salts
vergf
polymorphs
inhibitor
free base
Prior art date
Application number
MX2008001838A
Other languages
English (en)
Inventor
Yufeng Hong
Yi Li
Jia Liu
Anand Sistla
Bruce Joseph Elder
Paul Kenneth Isbester
Grant Jackson Palmer
Jonathan Stuart Salsbury
Luckner Gerard Ulysse
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2008001838A publication Critical patent/MX2008001838A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a sales y formas de base libre de N,2-dimetil-6-[7-(2-morfolinoetoxi)quinolin-4-iloxi]benzofuran-3- carboxamida. La invencion tambien se refiere a composiciones farmaceuticas de estas sales y formas de base libre y procedimiento para tratar trastornos tales como cancer usando tales composiciones.
MX2008001838A 2005-08-08 2006-07-27 Sales y polimorfos de un inhibidor de vegf-r. MX2008001838A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70633205P 2005-08-08 2005-08-08
US75018905P 2005-12-14 2005-12-14
PCT/IB2006/002171 WO2007017740A1 (en) 2005-08-08 2006-07-27 Salts and polymorphs of a vergf-r inhibitor

Publications (1)

Publication Number Publication Date
MX2008001838A true MX2008001838A (es) 2008-04-09

Family

ID=37320417

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001838A MX2008001838A (es) 2005-08-08 2006-07-27 Sales y polimorfos de un inhibidor de vegf-r.

Country Status (13)

Country Link
US (1) US7928226B2 (es)
EP (1) EP1915368A1 (es)
JP (1) JP4536688B2 (es)
KR (1) KR20080027923A (es)
AR (1) AR055600A1 (es)
AU (1) AU2006277742B2 (es)
BR (1) BRPI0614115A2 (es)
CA (1) CA2615760A1 (es)
IL (1) IL188851A0 (es)
MX (1) MX2008001838A (es)
RU (1) RU2369607C1 (es)
TW (1) TW200738689A (es)
WO (1) WO2007017740A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006277742B2 (en) 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
CA2770545C (en) * 2009-08-21 2015-11-03 F. Hoffmann-La Roche Ag Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2138498C1 (ru) * 1994-07-22 1999-09-27 Бык Гульден Ломберг Хемише Фабрик Гмбх Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе
WO1999032450A1 (en) * 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
CA2393265A1 (en) * 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1313726A1 (en) 2000-08-09 2003-05-28 AstraZeneca AB Quinoline derivatives having vegf inhibiting activity
WO2003074529A2 (en) 2002-03-01 2003-09-12 Pfizer Inc. iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
US8091987B2 (en) 2005-07-07 2012-01-10 Xaar Plc Ink jet print head with improved reliability
AU2006277742B2 (en) 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor

Also Published As

Publication number Publication date
US20090048254A1 (en) 2009-02-19
JP4536688B2 (ja) 2010-09-01
TW200738689A (en) 2007-10-16
RU2369607C1 (ru) 2009-10-10
JP2007045822A (ja) 2007-02-22
CA2615760A1 (en) 2007-02-15
US7928226B2 (en) 2011-04-19
BRPI0614115A2 (pt) 2011-03-09
KR20080027923A (ko) 2008-03-28
AR055600A1 (es) 2007-08-29
EP1915368A1 (en) 2008-04-30
RU2008104776A (ru) 2009-08-20
WO2007017740A1 (en) 2007-02-15
AU2006277742A1 (en) 2007-02-15
AU2006277742B2 (en) 2010-08-26
IL188851A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
MX2007013216A (es) Derivados de amida substituida como inhibidores de la proteina de cinasa.
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
TW200612892A (en) Novel compounds
TW200603798A (en) Disalt inhibitors of il-12 production
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL184292A0 (en) Treatment of drug-resistant proliferative disorders
MX2008001838A (es) Sales y polimorfos de un inhibidor de vegf-r.
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200621260A (en) Selected fused heterocyclics and uses thereof
MX2007013306A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.

Legal Events

Date Code Title Description
FG Grant or registration